GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Ranbaxy Laboratories Ltd (FRA:RLYG) » Definitions » Minority Interest

Ranbaxy Laboratories (FRA:RLYG) Minority Interest : €10.09 Mil (As of Sep. 2014)


View and export this data going back to . Start your Free Trial

What is Ranbaxy Laboratories Minority Interest?

Minority interest is the carrying amount of the equity interests owned by non-controlling shareholders, partners, or other equity holders in one or more of the entities included in the reporting entity's consolidated financial statements.

Ranbaxy Laboratories's minority interest for the quarter that ended in Sep. 2014 was €10.09 Mil.


Ranbaxy Laboratories Minority Interest Historical Data

The historical data trend for Ranbaxy Laboratories's Minority Interest can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Ranbaxy Laboratories Minority Interest Chart

Ranbaxy Laboratories Annual Data
Trend Dec04 Dec05 Dec06 Dec07 Dec08 Dec09 Dec10 Dec11
Minority Interest
Get a 7-Day Free Trial 9.96 10.29 7.86 10.85 11.75

Ranbaxy Laboratories Quarterly Data
Dec11 Dec12 Jun13 Sep14
Minority Interest 11.75 12.40 12.76 10.09

Ranbaxy Laboratories Minority Interest Calculation

Minority interest is the carrying amount of the equity interests owned by non-controlling shareholders, partners, or other equity holders in one or more of the entities included in the reporting entity's consolidated financial statements.


Ranbaxy Laboratories (FRA:RLYG) Business Description

Traded in Other Exchanges
N/A
Address
Ranbaxy Laboratories Ltd., is an integrated international pharmaceuticals company. It markets, produces and distributes pharmaceuticals products.

Ranbaxy Laboratories (FRA:RLYG) Headlines

No Headlines